New Horizon Health Signs Up Prenetics to Market Colorectal Test

00:04 EDT 23 Oct 2019 | ChinaBio Today

New Horizon Health, a Beijing company that develops tests for early diagnosis of GI and lung cancers, will partner with Prenetics to market ColoClear, its non-invasive colorectal cancer tests in Hong Kong and Southeast Asia. Prenetics is a global genetic testing company that operates its direct-to-consumer genomics business via two subsidiaries -- CircleDNA in Asia and DNAFit in Europe. New Horizon, which developed ColoClear specifically for people of Asian ethnicity, says the test detected colon cancer with 92% sensitivity in clinical trials. More details....

Share this with colleagues:

Original Article: New Horizon Health Signs Up Prenetics to Market Colorectal Test


More From BioPortfolio on "New Horizon Health Signs Up Prenetics to Market Colorectal Test"

Quick Search

Relevant Topics

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...